{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:10:38Z","timestamp":1793070638703,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.leukres.2012.10.020","type":"journal-article","created":{"date-parts":[[2012,11,20]],"date-time":"2012-11-20T06:47:26Z","timestamp":1353394046000},"page":"214-220","source":"Crossref","is-referenced-by-count":234,"title":["Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?"],"prefix":"10.1016","volume":"37","author":[{"given":"Hans Carl","family":"Hasselbalch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.leukres.2012.10.020_bib0005","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"Mechanisms of disease: the myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.10.020_bib0010","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.10.020_bib0015","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"TET2 mutations in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.10.020_bib0020","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.leukres.2012.10.020_bib0025","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.10.020_bib0030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"July 7 (1)","key":"10.1016\/j.leukres.2012.10.020_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2012.10.020_bib0040","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ajh.22166","article-title":"Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm","volume":"86","author":"Rumi","year":"2011","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.leukres.2012.10.020_bib0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2012.10.020_bib0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3324\/haematol.2010.038299","article-title":"Pathophysiology of thrombosis in myeloproliferative neoplasms","volume":"96","author":"Landolfi","year":"2011","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.leukres.2012.10.020_bib0055","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2012.10.020_bib0060","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"25","key":"10.1016\/j.leukres.2012.10.020_bib0065","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2012.10.020_bib0070","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: wounds that do not heal, Similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.leukres.2012.10.020_bib0075","first-page":"39","article-title":"Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism","volume":"40","author":"Hasselbalch","year":"1993","journal-title":"Dan Med Bull"},{"issue":"9255","key":"10.1016\/j.leukres.2012.10.020_bib0080","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"issue":"6917","key":"10.1016\/j.leukres.2012.10.020_bib0085","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.leukres.2012.10.020_bib0090","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri1703","article-title":"NF-kappaB: linking inflammation and immunity to cancer development and progression","volume":"5","author":"Karin","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.leukres.2012.10.020_bib0095","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/ijc.23173","article-title":"Inflammation and cancer: an ancient link with novel potentials","volume":"121","author":"Hussain","year":"2007","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2012.10.020_bib0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/07853890903405753","article-title":"Molecular pathways and targets in cancer-related inflammation","volume":"42","author":"Mantovani","year":"2010","journal-title":"Ann Med"},{"key":"10.1016\/j.leukres.2012.10.020_bib0105","doi-asserted-by":"crossref","first-page":"10280","DOI":"10.1158\/0008-5472.CAN-08-1957","article-title":"Methylation of polycomb target genes in intestinal cancer is mediated by inflammation","author":"Hahn","year":"2008","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.leukres.2012.10.020_bib0110","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1634\/stemcells.2008-0377","article-title":"Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis","volume":"26","author":"Bogani","year":"2008","journal-title":"Stem Cells"},{"issue":"November (11)","key":"10.1016\/j.leukres.2012.10.020_bib0115","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3324\/haematol.13043","article-title":"Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders","volume":"93","author":"Fourouclas","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.leukres.2012.10.020_bib0120","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/jclinpath-2011-200175","article-title":"Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation","volume":"64","author":"Barrio","year":"2011","journal-title":"J Clin Pathol"},{"issue":"10","key":"10.1016\/j.leukres.2012.10.020_bib0125","first-page":"1398","article-title":"Epigenetics and mutations in chronic myeloproliferative neoplasms","volume":"96","author":"Vannucchi","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.10.020_bib0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2012.10.020_bib0135","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2012.10.020_bib0140","first-page":"560","article-title":"Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis","volume":"118","author":"Popivanova","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2012.10.020_bib0145","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1172\/JCI35213","article-title":"Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice","volume":"118","author":"Kujawski","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2012.10.020_bib0150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nature06905","article-title":"NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha","volume":"453","author":"Rius","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.leukres.2012.10.020_bib0155","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/carcin\/bgs006","article-title":"DNA methylation and colitis-associated cancer","volume":"33","author":"Hartnett","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.leukres.2012.10.020_bib0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","article-title":"Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer","volume":"21","author":"Grivennikov","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.leukres.2012.10.020_bib0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1126\/science.8140422","article-title":"Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6","volume":"264","author":"Zhong","year":"1994","journal-title":"Science"},{"issue":"Pt 2","key":"10.1016\/j.leukres.2012.10.020_bib0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj3340297","article-title":"Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway","volume":"334","author":"Heinrich","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/j.leukres.2012.10.020_bib0175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/gut.2009.184176","article-title":"Disease-related expression of the IL6\/STAT3\/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis","volume":"59","author":"Li","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.leukres.2012.10.020_bib0180","doi-asserted-by":"crossref","first-page":"14133","DOI":"10.1073\/pnas.2232790100","article-title":"SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer","volume":"100","author":"He","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2012.10.020_bib0185","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.4049\/jimmunol.176.8.5015","article-title":"Histone hyperacetylation is associated with amelioration of experimental colitis in mice","volume":"176","author":"Glauben","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2012.10.020_bib0190","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/ibd.21573","article-title":"DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status","volume":"17","author":"Saito","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.leukres.2012.10.020_bib0195","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1541-7786.MCR-09-0496","article-title":"Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6 Mo","volume":"8","author":"Foran","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2012.10.020_bib0200","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.4049\/jimmunol.1002805","article-title":"An endogenously anti-inflammatory role for methylation in mucosal inflammation identified through metabolite profiling","volume":"186","author":"Kominsky","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2012.10.020_bib0205","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ccr.2011.09.012","article-title":"Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands","volume":"20","author":"O\u2019Hagan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2012.10.020_bib0210","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00423-006-0073-1","article-title":"Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair","volume":"391","author":"Bartsch","year":"2006","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.leukres.2012.10.020_bib0215","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1096\/fj.02-0752rev","article-title":"Oxidative DNA damage: mechanisms, mutation, and disease","volume":"17","author":"Cooke","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.leukres.2012.10.020_bib0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mrfmmm.2010.03.007","article-title":"Chronic inflammation and mutagenesis","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res"},{"key":"10.1016\/j.leukres.2012.10.020_bib0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/10408360903142326","article-title":"Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers","author":"Giustarini","year":"2009","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.leukres.2012.10.020_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrfmmm.2011.10.012","article-title":"Gene susceptibility to oxidative damage: from single nucleotide polymorphisms to function","volume":"731","author":"Simonelli","year":"2012","journal-title":"Mutat Res"},{"issue":"21","key":"10.1016\/j.leukres.2012.10.020_bib0235","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.020_bib0240","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.leukres.2009.04.038","article-title":"Does oxidative damage contribute to the generation of leukemia?","volume":"33","author":"Austin","year":"2009","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.leukres.2012.10.020_bib0245","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.leukres.2009.02.027","article-title":"The gene encoding thioredoxin-interacting protein (TXNIP) is a frequent virus integration site in virus-induced mouse leukemia and is overexpressed in a subset of AML patients","volume":"33","author":"Erkeland","year":"2009","journal-title":"Leuk Res"},{"issue":"24","key":"10.1016\/j.leukres.2012.10.020_bib0250","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2012.10.020_bib0255","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3324\/haematol.2011.055392","article-title":"The JAK2 46\/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?","volume":"96","author":"Hermouet","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.10.020_bib0260","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1089\/ars.2008.2114","article-title":"Regulation of reactive oxygen species and genomic instability in hematopoietic stem cells","volume":"10","author":"Naka","year":"2008","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.leukres.2012.10.020_bib0265","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cell.2007.01.003","article-title":"FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress","volume":"128","author":"Tothova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2012.10.020_bib0270","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nature02989","article-title":"Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells","volume":"431","author":"Ito","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2012.10.020_bib0275","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1182\/blood-2007-05-087759","article-title":"A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche","volume":"110","author":"Jang","year":"2007","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.leukres.2012.10.020_bib0280","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1182\/blood-2011-05-355362","article-title":"The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels","volume":"118","author":"Merchant","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2012.10.020_bib0285","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/ars.2007.1957","article-title":"Redox regulation of cell survival","volume":"10","author":"Trachootham","year":"2008","journal-title":"Antioxid Redox Signal"},{"issue":"34","key":"10.1016\/j.leukres.2012.10.020_bib0290","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.2174\/138161206779010549","article-title":"The redox regulation of thiol dependent signaling pathways in cancer","volume":"12","author":"Giles","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.leukres.2012.10.020_bib0295","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.stem.2007.07.017","article-title":"FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system","volume":"1","author":"Tothova","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.leukres.2012.10.020_bib0300","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/nm1320","article-title":"The antioxidant function of the p53 tumor suppressor","volume":"11","author":"Sablina","year":"2005","journal-title":"Nat Med"},{"issue":"37","key":"10.1016\/j.leukres.2012.10.020_bib0305","doi-asserted-by":"crossref","first-page":"25692","DOI":"10.1074\/jbc.M800517200","article-title":"Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells","volume":"283","author":"Yalcin","year":"2008","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.leukres.2012.10.020_bib0310","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1272\/jnms.78.138","article-title":"Development of maintenance of cancer stem cells under chronic inflammation","volume":"78","author":"Toshihiko","year":"2011","journal-title":"J Nippon Med Sch"},{"issue":"1","key":"10.1016\/j.leukres.2012.10.020_bib0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1568-7864(01)00007-6","article-title":"ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage","volume":"1","author":"Barzilai","year":"2002","journal-title":"DNA Repair (Amst)"},{"issue":"7281","key":"10.1016\/j.leukres.2012.10.020_bib0320","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.leukres.2012.10.020_bib0325","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.stem.2007.02.001","article-title":"Foxo3a is essential for maintenance of the hematopoietic stem cell pool","volume":"1","author":"Miyamoto","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.leukres.2012.10.020_bib0330","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.molcel.2007.10.035","article-title":"FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2","volume":"28","author":"Bakker","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.leukres.2012.10.020_bib0335","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mrfmmm.2009.09.007","article-title":"A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders","volume":"690","author":"Kim","year":"2010","journal-title":"Mutat Res"},{"key":"10.1016\/j.leukres.2012.10.020_bib0340","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2012.10.020_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrfmmm.2010.06.011","article-title":"Chronic inflammation, mutation and human disease","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res"},{"issue":"March 1 (5)","key":"10.1016\/j.leukres.2012.10.020_bib0350","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1158\/0008-5472.CAN-10-3018","article-title":"High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors","volume":"71","author":"Rushworth","year":"2011","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.leukres.2012.10.020_bib0355","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1172\/JCI31772","article-title":"TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells","volume":"117","author":"Li","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.leukres.2012.10.020_bib0360","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2008.06.002","article-title":"Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer\u2014time to change our therapeutic attitude with early upfront treatment?","volume":"33","author":"Hasselbalch","year":"2009","journal-title":"Leuk Res"},{"issue":"8642","key":"10.1016\/j.leukres.2012.10.020_bib0365","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0140-6736(89)92273-3","article-title":"Detection of retrovirus in patients with myeloproliferative disease","volume":"1","author":"Boyd","year":"1989","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.leukres.2012.10.020_bib0370","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.exphem.2004.03.003","article-title":"Human endogenous retrovirus (HERV-K) particles in megakaryocytes cultured from essential thrombocythemia peripheral blood stem cells","volume":"32","author":"Morgan","year":"2004","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.leukres.2012.10.020_bib0375","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","article-title":"Whole Blood Transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis","volume":"87","author":"Skov","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2012.10.020_bib0380","unstructured":"Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol [Epub ahead of print]."},{"key":"10.1016\/j.leukres.2012.10.020_bib0385","unstructured":"Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res [Epub ahead of print]."},{"issue":"3","key":"10.1016\/j.leukres.2012.10.020_bib0390","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2012.10.020_bib0395","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2012.10.020_bib0400","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2012.10.020_bib0405","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.leukres.2012.10.020_bib0410","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.020_bib0415","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1179\/102453309X12473408860587","article-title":"Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha interferon2b in polycythemia vera: a report on molecular response patterns in seven patients in sustained complete hematological remission","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"issue":"21","key":"10.1016\/j.leukres.2012.10.020_bib0420","first-page":"280","article-title":"Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon {alpha}-2a (peg-IFN{alpha}-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial","volume":"118","author":"Turlure","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2012.10.020_bib0425","doi-asserted-by":"crossref","unstructured":"Gowin K, Thapaliya P, Samuelsson J, Harrison C, Radia D, Andreasson B, et al. Experience with pegylated Interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012 [Epub ahead of print].","DOI":"10.3324\/haematol.2011.061390"},{"issue":"11","key":"10.1016\/j.leukres.2012.10.020_bib0430","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2012.10.020_bib0435","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/138945011794815275","article-title":"Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives","volume":"12","author":"Hasselbalch","year":"2011","journal-title":"Curr Drug Targets"},{"issue":"6","key":"10.1016\/j.leukres.2012.10.020_bib0440","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/ehm.11.63","article-title":"A new era for IFN-\u03b1 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms","volume":"4","author":"Hasselbalch","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"18","key":"10.1016\/j.leukres.2012.10.020_bib0445","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.10.020_bib0450","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/hep.23544","article-title":"Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta","volume":"51","author":"You","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.leukres.2012.10.020_bib0455","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2009.10.014","article-title":"An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation","volume":"139","author":"Iliopoulos","year":"2009","journal-title":"Cell"},{"issue":"January 31 (1)","key":"10.1016\/j.leukres.2012.10.020_bib0460","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/gm307","article-title":"From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms","volume":"4","author":"Martin","year":"2012","journal-title":"Genome Med"},{"key":"10.1016\/j.leukres.2012.10.020_bib0465","doi-asserted-by":"crossref","first-page":"e16652","DOI":"10.1371\/journal.pone.0016652","article-title":"The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1","volume":"6","author":"Nex\u00f8","year":"2011","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.leukres.2012.10.020_bib0470","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.leukres.2012.10.020_bib0475","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","article-title":"Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?","volume":"30","author":"Hasselbalch","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2012.10.020_bib0480","article-title":"A mechanistic rationale for the use of statins to enhance JAK2 inhibitor therapy in MPNs","volume":"118","author":"Griner","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2012.10.020_bib0485","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNa activates dormant haematopoietic stem cells in vivo","volume":"7240","author":"Essers","year":"2009","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.leukres.2012.10.020_bib0490","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2012.10.020_bib0495","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","article-title":"Increased in ciculating CD+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myelopoliferative neoplasms during treatment with IFN-\u03b1","volume":"118","author":"Riley","year":"2011","journal-title":"Blood"},{"issue":"8A","key":"10.1016\/j.leukres.2012.10.020_bib0500","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1582-4934.2009.00827.x","article-title":"Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives","volume":"13","author":"Vannucchi","year":"2009","journal-title":"J Cell Mol Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612004328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612004328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T03:56:01Z","timestamp":1540094161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612004328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0145212612004328"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.10.020","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}